Merck announces presentation of interim data from phase 1B study of MK-3475, investigational anti-PD-1 immunotherapy
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
List view / Grid view
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
23 October 2013 | By Stallergenes
Sublingual immunotherapy sales continued to grow in the 3rd quarter thanks notably to the fast adoption of Oralair® in France...
1 October 2013 | By Merck
An abstract (# 2416) published today summarized preliminary findings from 38 patients with NSCLC treated with MK-3475...
27 March 2013 | By Merck
“We are pleased to have achieved this important milestone..."